Volume 50 | Number 4 | August 2015

Abstract List

Gery P. Guy Ph.D., M.P.H, Joseph Lipscomb Ph.D., Theresa W. Gillespie Ph.D., M.A., Michael Goodman M.D., M.P.H., Lisa C. Richardson M.D., M.P.H., Kevin C. Ward Ph.D.


To examine factors associated with guideline‐concordant adjuvant therapy among breast cancer patients in a rural region of the United States and to present an advancement in quality‐of‐care assessment in the context of multiple treatments.

Data Sources

Chart abstraction on initial therapy received by 868 women diagnosed with primary, invasive, early‐stage breast cancer in a largely rural region of southwest eorgia.

Study Design

Using multivariable logistic regression, we examined predictors of adjuvant chemo‐, radiation, and hormonal therapy regimens defined as guideline‐concordant according to the 2000 National Institutes of Health Consensus Development Conference Statement.

Principal Findings

Overall, 35.2 percent of women received guideline‐concordant care for all three adjuvant therapies. Higher socioeconomic status was associated with receiving guideline‐concordant care for all three adjuvant therapies jointly, and for chemotherapy. Compared with private insurance, having Medicaid was associated with guideline‐concordant chemotherapy. Unmarried women were more likely to be nonconcordant for chemotherapy and radiation therapy. Increased age predicted nonconcordance for adjuvant therapies jointly, for chemotherapy, and for hormonal therapy.


A number of factors were independently associated with receiving guideline‐concordant adjuvant therapy. Identifying and addressing factors that lead to nonconcordance may reduce disparities in treatment and survival.